MedTrace Logo

Safety and Efficacy of TD0025 (Rocket1h) for Treatment of Erectile Dysfunction

NCT02798159 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2018-10-11

No results posted yet for this study

Summary

The purpose of this study is to identify the optimal dose(s) of TD0025 for treatment of erectile dysfunction (phase II) and to investigate if treatment of erectile dysfunction with the optimal dose of TD0025 taken as needed over one month is non-inferior than Sildenafil Citrate taken as needed over one month (phase III)

Conditions

Interventions

DRUG

TD0025

DRUG

Sildenafil Citrate 50mg

Sponsors & Collaborators

  • Vietstar Biomedical Research

    lead INDUSTRY

Principal Investigators

  • Nguyen Quang, MD. PhD. · Men Sexual Health Centre, Vietnam- Germany Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2018-03-01
Completion
2018-07-01

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02798159 on ClinicalTrials.gov